Skip to main content
MedinCell signs a licence agreement with the Medicines Patent Pool to fight malaria transmission, as part of its global health mission
September 13, 2022
MedinCell secures additional 20 million euros financing with the European Investment Bank (EIB)
September 5, 2022
Phase 3 study to be initiated for second long-acting injectable antipsychotic using MedinCell’s technology
August 29, 2022
An impact company committed to improving the health of patients worldwide, MedinCell publishes its 2021-2022 ESG annual report
August 17, 2022
Participation terms in the Combined General Meeting
August 8, 2022
MedinCell announces the availability of its 2021/2022 Universal Registration Document including the Annual Financial Report
July 29, 2022
MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000
July 27, 2022
MedinCell announces its full year financial results April 2021 – March 2022
June 14, 2022
Videoconference and release of fiscal 2021-2022 financial results on June 14, 2022
June 7, 2022
MedinCell: US Pharma Development expert Richard Malamut, MD becomes Chief Medical Officer
May 9, 2022
